PubMed Health⌕ Search

Biomedical subjects

J C Yip

Publications and source records attributed to J C Yip.

2 recordsLinked to original sources

Genetic variation among 129 substrains: practical consequences.

We designed a series of experiments to define the role of IFN-gamma in cellular interactions mediating graft rejection by assessing the rejection of H-Y disparate grafts in both ligand and receptor knockout mice and their control inbred strain. In the course of these studies it became apparent that neither knockout strain is histocompatible with the putative control and that the putative control is not histocompatible with either knockout strain. In the process of deducing why this might be so, it became apparent that the putative control is not an inbred strain of mouse. Thus, in the absence of rigorous genetic control, the utility of such knockout strains of mice for assessing the effects of cytokines and receptors in transplantation and autoimmunity is limited.

Animals↗

Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.

OBJECTIVE: To assess the effect on various aspects of carbohydrate and lipid metabolism of administering a quick-release formulation of bromocriptine (Ergoset) to obese, nondiabetic, hyperinsulinemic women. RESEARCH DESIGN AND METHODS: Hourly concentrations of prolactin, glucose, insulin, free fatty acid (FFA), and triglyceride were measured for 24 h before and after approximately 8 weeks of treatment with Ergoset. In addition, fasting lipid and lipoprotein concentrations and the steady-state plasma glucose (SSPG) concentration in response to a continuous infusion of somatostatin, insulin, and glucose were determined before and after Ergoset administration. RESULTS: Circulating prolactin concentrations were dramatically decreased (P < 0.001) following treatment, associated with a significant fall (P < 0.05) in 24-h-long plasma glucose, FFA, and triglyceride concentrations. Neither circulating plasma insulin concentrations nor the ability of insulin to mediate glucose disposal changed with treatment. Finally, fasting total cholesterol fell (P < 0.05) and the ratio of total to HDL cholesterol decreased (P = 0.06) in association with Ergoset treatment. CONCLUSIONS: The fact that significant metabolic improvement was seen in the obese nondiabetic hyperinsulinemic women studied suggests that Ergoset could be of therapeutic benefit in clinical conditions of hyperglycemia and/or dyslipidemia.

Administration, Oral↗